Chlorpromazine
Chlorpromazine, Thorazine (chlorpromazine) is a small molecule pharmaceutical. Chlorpromazine was first approved as Thorazine on 1982-01-01. It is used to treat acute intermittent porphyria, anxiety disorders, attention deficit and disruptive behavior disorders, child behavior disorders, and hiccup amongst others in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. In addition, it is known to target alpha-2B adrenergic receptor, D(3) dopamine receptor, short transient receptor potential channel 5, D(4) dopamine receptor, D(1A) dopamine receptor, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 2C, histamine H1 receptor, alpha-2C adrenergic receptor, D(2) dopamine receptor, 5-hydroxytryptamine receptor 7, alpha-2A adrenergic receptor, and 5-hydroxytryptamine receptor 6.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Chlorpromazine (discontinued: Chlorpromazine, Promapar, Sonazine, Thorazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aunt bees five flavors | OTC monograph final | 2015-03-12 |
| bluzen - winter pine, wintermint, peppermint - kit | OTC monograph not final | 2020-09-11 |
| bluzen hand sanitizer wintermint | OTC monograph not final | 2020-09-10 |
| chlorpromazine | ANDA | 2024-04-24 |
| chlorpromazine hci | ANDA | 2023-03-09 |
| chlorpromazine hydrochloride | ANDA | 2024-10-17 |
| giant eagle wintermint with fluoride | OTC monograph final | 2019-10-22 |
| giant eagle wintermint zero alcohol | OTC monograph final | 2019-10-22 |
| hey humans whitening wintermint chill | OTC monograph final | 2021-03-01 |
| level wintermint five whitening formula anticavity | OTC monograph final | 2011-05-09 |
Show 8 more
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | 1 | 4 | 5 | 12 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | — | 1 | 2 | 1 | 5 |
| Emergencies | D004630 | — | — | — | — | — | 1 | 1 | 2 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | 1 | 1 | 2 |
| Aggression | D000374 | EFO_0003015 | — | — | — | — | 1 | — | 1 |
| Psychiatric emergency services | D004637 | — | — | — | — | — | 1 | — | 1 |
| Mania | D000087122 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | 1 | — | 1 | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | 1 | — | 1 | 2 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | — | 1 | — | — | 2 |
| Delirium | D003693 | — | R41.0 | — | 2 | 2 | — | — | 2 |
| Covid-19 | D000086382 | — | — | — | 1 | 2 | — | — | 2 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | 1 | — | — | 1 |
| Neonatal abstinence syndrome | D009357 | EFO_0005799 | P96.1 | — | — | 1 | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | 1 | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | 1 | — | — | — | 2 |
| Colonic neoplasms | D003110 | — | C18 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psychomotor agitation | D011595 | — | — | 1 | — | — | — | — | 1 |
| Acute intermittent porphyria | D017118 | — | — | 1 | — | — | — | — | 1 |
| Oral manifestations | D009912 | — | — | 1 | — | — | — | — | 1 |
| Tetanus | D013742 | EFO_0005593 | A35 | 1 | — | — | — | — | 1 |
| Porphyrias | D011164 | EFO_0000665 | — | 1 | — | — | — | — | 1 |
| Ischemic stroke | D000083242 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | — | — | 1 | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
| Behavior | D001519 | GO_0007610 | — | — | — | — | — | 1 | 1 |
| Social skills | D066107 | — | — | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
| Muscle spasticity | D009128 | HP_0001257 | — | — | — | — | — | 1 | 1 |
| Motivation | D009042 | — | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Chlorpromazine |
| INN | chlorpromazine |
| Description | Chlorpromazine is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. It has a role as a phenothiazine antipsychotic drug, an antiemetic, a dopaminergic antagonist, an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor and an anticoronaviral agent. It is a member of phenothiazines, an organochlorine compound and a tertiary amine. |
| Classification | Small molecule |
| Drug class | Typical antipsychotic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21 |
Identifiers
| PDB | — |
| CAS-ID | 50-53-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL71 |
| ChEBI ID | 3647 |
| PubChem CID | 2726 |
| DrugBank | DB00477 |
| UNII ID | U42B7VYA4P (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Chlorpromazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 33,104 documents
View more details
Safety
Black-box Warning
Black-box warning for: Chlorpromazine, Chlorpromazine hci, Chlorpromazine hydrochloride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,349 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use